Clinical trials: sponsored by European Organisation for Research and Treatment of Cancer - EORTC
- Sponsor European Organisation for Research and Treatment of Cancer - EORTC
- Age group Children (under 18)
Hodgkin Lymphoma
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel.
- Trial name
- RADAR (NCT04685616)
- Testing
- Involved site radiotherapy, Doxorubicin, Bleomycin
- Where
- 72 sites in United States, Australia and 10 more
- Volunteers
- 1,042 people
- Sponsor
- University College, London
All Tumor Types
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer…
- Trial name
- SPECTA (NCT02834884)
- Testing
- RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen
- Where
- 136 sites in Austria, Belgium and 18 more
- Volunteers
- 4,975 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Germ Cell Tumor, Teratoma
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
This randomized phase III trial studies how well standard-dose combination chemotherapy works compared to high-dose combination chemotherapy and stem cell transplant in treating patients with germ cell tumors that have returned…
- Conditions
- Germ Cell Tumor, Teratoma, Choriocarcinoma, Germinoma
- Trial name
- NCT02375204
- Testing
- paclitaxel, ifosfamide, cisplatin
- Where
- 125 sites in United States, Australia and 10 more
- Volunteers
- 420 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Psychosocial Effects of Cancer and Its Treatment
Assessing Women's Attitudes About the Risk of Infertility Related to Adjuvant Therapy for Early Breast Cancer
RATIONALE: Adjuvant therapy given after surgery for early breast cancer may cause infertility. Assessing young women's attitudes and feelings about the risk of infertility may help improve the ability to plan effective treatment.
- Conditions
- Breast Cancer, Psychosocial Effects of Cancer and Its Treatment, Sexual Dysfunction and Infertility, Sexuality and Reproductive Issues
- Trial name
- NCT00062400
- Testing
- psychosocial assessment and care
- Where
- 27 sites in Belgium, Chile and 13 more
- Volunteers
- 385 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Letrozole After Tamoxifen in Treating Women With Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen.
- Trial name
- NCT00003140
- Testing
- letrozole
- Where
- 57 sites in Canada, United Kingdom
- Volunteers
- 5,187 people
- Sponsor
- NCIC Clinical Trials Group
Acute Lymphoblastic Leukemia (ALL)
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
The main goal of this study is to improve the outcome of children and adolescents with acute lymphoblastic leukemia with high risk first relapse by optimization of treatment strategies within a large international trial and the…
- Trial name
- NCT03590171
- Testing
- Bortezomib
- Where
- 15 sites in Australia, Austria and 13 more
- Volunteers
- 250 people
- Sponsor
- Charite University, Berlin, Germany
Medulloblastoma
Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma
Medulloblastoma is a rare brain malignancy, mainly affecting children. Treatment of this rapidly growing tumor begins with maximal surgical removal plus radiation and chemotherapy. Treatment toxicity is high.
- Trial name
- PersoMed-I (NCT04402073)
- Testing
- Sonidegib, Cisplatin, Lomustine
- Where
- 50 sites in Australia, Austria and 6 more
- Volunteers
- 20 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with combination chemotherapy may kill more tumor cells.
- Trial name
- NCT00002462
- Testing
- bleomycin sulfate, doxorubicin hydrochloride, mechlorethamine hydrochloride
- Where
- 56 sites in Belgium, Egypt and 7 more
- Volunteers
- 615 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00005584
- Testing
- bleomycin sulfate, ABVD regimen, BEACOPP regimen
- Where
- 121 sites in Belgium, France and 8 more
- Volunteers
- 1,649 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00049595
- Testing
- bleomycin sulfate, filgrastim, pegfilgrastim
- Where
- 140 sites in Australia, Belgium and 11 more
- Volunteers
- 552 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma
RATIONALE: Radiation therapy uses high-energy x-rays to kill cancer cells. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00379041
- Testing
- bleomycin sulfate, doxorubicin hydrochloride, mechlorethamine hydrochloride
- Volunteers
- 1,158 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer, Prostate Cancer
OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)
The goal of this clinical trial is to evaluate single-fraction metastases-directed SBRT in the broader radiation oncology community and to compare its safety and efficacy profile with the current Standard of Care (SoC) of…
- Conditions
- Breast Cancer, Prostate Cancer, NSCLC, Colorectal Cancer
- Trial name
- SPRINT (NCT06462963)
- Testing
- single-fraction SBRT, multiple-fraction SBRT
- Where
- 15 sites in Belgium, Italy and 2 more
- Volunteers
- 302 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cancer
E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe
The primary objective is the collection of real-world data of cancer patients treated with radiotherapy, to support radiotherapy research and to provide evidence of the role of radiation oncology in a multidisciplinary approach.
- Trial name
- E²-RADIatE (NCT03818503)
- Where
- 77 sites in Austria, Belgium and 12 more
- Volunteers
- 2,000 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Dissecting the Pathways of Therapy Resistance in Early Breast Cancer
Within the 1st step MINDACT patients who have already relapsed will be asked to participate. For these patients a biopsy of the metastasis should have been taken.
- Trial name
- MINDACTRelapse (NCT04995575)
- Testing
- collection of the biopsy, blood samples
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 31 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Acute Lymphoblastic Leukemia (ALL)
International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010
The main goal of this study is to improve the outcome of children and adolescents with standard risk (SR) first relapsed acute lymphoblastic leukemia.
- Trial name
- NCT01802814
- Testing
- SR-A + Epratuzumab, SR-B + Epratuzumab
- Where
- 17 sites in Australia, Austria and 15 more
- Volunteers
- 700 people
- Sponsor
- Charite University, Berlin, Germany
Gastric and Esophagogastric Junction Adenocarcinoma
Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence
The primary objective of the trial is to investigate if nivolumab plus ipilimumab given as adjuvant treatment improve disease free survival (DFS) in patients with stage Ib-IVa gastric and esophagogastric junction adenocarcinoma…
- Trial name
- VESTIGE (NCT03443856)
- Testing
- Nivolumab and Ipilimumab, chemotherapy
- Where
- 28 sites in Czechia, France and 7 more
- Volunteers
- 197 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor
CREATE: Cross-tumoral Phase 2 With Crizotinib
The study will primarily assess the antitumor activity of crizotinib in a variety of tumors with alterations in ALK and/or MET pathways.
- Conditions
- Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor, Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1, Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma
- Trial name
- CREATE (NCT01524926)
- Testing
- Crizotinib (PF-02341066)
- Where
- 25 sites in Belgium, France and 8 more
- Volunteers
- 582 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- H10 (NCT00433433)
- Testing
- ABVD q4 weeks, BEACOPP escalated q3 weeks, IN-RT 30 Gy (+ boost 6 Gy residual)
- Where
- Netherlands
- Volunteers
- 1,952 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Glioblastoma
Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas
This study was conducted to evaluate the efficacy and safety of depatuxizumab mafodotin (ABT-414) alone or with temozolomide versus temozolomide or lomustine alone in adult participants with recurrent glioblastoma.
- Trial name
- INTELLANCE-2 (NCT02343406)
- Testing
- Depatuxizumab mafodotin, Temozolomide, Lomustine
- Where
- 102 sites in United States, Australia and 19 more
- Volunteers
- 266 people
- Sponsor
- AbbVie
Esophageal Cancer
Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy with radiation therapy before surgery may shrink the tumor so it can be…
- Trial name
- NCT00047112
- Testing
- cisplatin, fluorouracil, conventional surgery
- Where
- 73 sites in Belgium, France and 2 more
- Volunteers
- 195 people
- Sponsor
- Federation Francophone de Cancerologie Digestive